Clayton, Dubilier & Rice (CD&R) said on Tuesday it would pay 108
pence a share in cash for Huntsworth <HNTS.L>, which provides
marketing and medical communications services to pharmaceutical
companies.
That's a 50% premium to the stock's closing price on Monday.
However, Huntsworth shares surged beyond the bid price to as
high as 110.7 pence, suggesting some investors think a
counter-bid is possible for the fast-growing British firm.
"This looks an excellent price for the bidding company" said
Peel Hunt analysts, who have a target price of 120 pence for
Huntsworth shares. "This modest valuation ... (leaves) the door
ajar for speculation on the potential for a competing approach".
CD&R said Huntsworth's underlying markets, the United States and
Europe, were attractive and underpinned by stable pharma
industry trends, adding it intended to help Huntsworth with
future acquisitions.
"Our vision for Huntsworth is shared with management, who have
demonstrated an ability to drive organic growth and execute
accretive add-on acquisitions," said Liam Fitzgerald, adviser to
CD&R funds.
In a separate statement, Huntsworth reported a 27% jump in
pretax profit for 2019, as its communications division returned
to growth and its medical arm went from strength to strength.
"Healthcare remains our focus for growth and investment, as it
continues to be a fast-growing sector led by increasing global
demand for new drugs to help ageing populations," said
Huntsworth chief executive Paul Taaffe.
"This demand is driving a complex marketplace that requires a
combination of higher margin consultancy services, medical
affairs and more effective marketing".
The acquisition is the latest by a U.S. private equity firm in
Britain, where a drop in the value of the pound has spurred
dealmaking since the country voted to leave the European Union.
Buyout firm Advent, for example, is taking British defense and
aerospace group Cobham private, while Blackstone is buying
Madame Tussauds owner Merlin.
Huntsworth's directors were advised by Rothschild & Co on the
financial terms of the deal, while BofA Securities, Houlihan
Lokey and RBC Capital Markets were among advisers to CD&R.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Bernard
Orr and Mark Potter)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|